[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367411-105":59,"doc-detail-367411-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","evaluating-the-performance-of-the-xpert-hpv-assay-in-detecting-hpv-positive-cases-in-morocco-article","Evaluating the performance of the Xpert HPV assay in detecting HPV positive cases in Morocco - Article","","Recently, the World Health Organization recommended integrating HPV testing into cervical cancer screening programs globally. This study compared the GeneXpert assay with PCR-sequencing for HPV detection and genotyping to assess feasibility for HPV molecular testing in screening. A total of 1000 women aged 30 or 40 across four Moroccan regions were recruited; 979 valid samples remained after exclusions. HPV prevalence was 4.0% by PCR and 5.0% by Xpert, with 5.7% combined and 97.5% concordance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluating-the-performance-of-the-xpert-hpv-assay-in-detecting-hpv-positive-cases-in-morocco-article/367411/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluating-the-performance-of-the-xpert-hpv-assay-in-detecting-hpv-positive-cases-in-morocco-article/367411.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the purpose of comparing GeneXpert and PCR-sequencing in this study?","Question",{"text":113,"@type":114},"To compare assay performance for HPV detection and genotyping and to assess feasibility of incorporating HPV molecular testing into cervical cancer screening programs.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many participants and valid samples were included in the analysis?",{"text":118,"@type":114},"The study recruited 1000 women; after excluding 21 invalid tests, 979 samples were analyzed.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the study report about HPV prevalence and agreement between methods?",{"text":122,"@type":114},"HPV prevalence was 4.0% by PCR and 5.0% by Xpert, with 5.7% combined, and a 97.5% concordance rate between tests.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},367411,1790211249,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Tumour Virus Research 19 (2025) 200318  \nContents lists available at ScienceDirect  \nTumour Virus Research  \njournal [homepage:](homepage: www.journals.elsevier.com/tumour-virus-research)[ www.journals.elsevier.com/tumour-virus-research](homepage: www.journals.elsevier.com/tumour-virus-research)  \n| Evaluating the performance of the Xpert HPV assay in detecting HPV positive cases in Morocco\u003Cbr>Said Ali Yerima,b , Youssef Chami Khazrajic, Rachid Bekkali c, Maria Bennaic, Nassiba Bahrad, Imane Chaouia, Fatima Zahra Chellatd, Zineb Gaizic, Nabil Tachfoutie, Anas Benabdellahe, Bouchra Belkadib, Mohammed Attaleba, Mohamed Amine Berrahod,e,\u003Cbr>Mohammed El Mzibria,* \u003Cbr>a Biology and Medical Research Unit, Centre National de L’Energie, des Sciences et Techniques Nucl´eaires (CNESTEN), Rabat, Morocco b Microbiology and Molecular Biology Laboratory, Faculty of Sciences, Mohammed V University, in Rabat, Morocco\u003Cbr>c Fondation Lalla Salma– Pr´evention et Traitement des Cancers, Rabat, Morocco d Cancer Research Institute, Fez, Morocco\u003Cbr>e Laboratory of Epidemiology and Public Health, Faculty of Medicine, Sidi Mohammed Ben Abdellah University, Fez, Morocco |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords:\u003Cbr>PCR\u003Cbr>GeneXpert Sequencing Screening\u003Cbr>Cervical cancer Human papillomavirus |  | Recently, the World Health Organization recommended integrating HPV testing into cervical cancer screening programs globally. This study aimed to compare the GeneXpert assay with PCR-sequencing for HPV detection and genotyping to assess the feasibility of incorporating HPV molecular testing into cervical cancer screening. A total of 1000 women aged 30 or 40 from rural and urban areas across four regions in Morocco with high sexually transmitted infection prevalence were recruited. After excluding 21 invalid tests, DNA testing on the remaining 979 samples showed an HPV prevalence of 4.0 %(39/979) by PCR and 5.0 %(49/979) by Xpert, with an overall prevalence of 5.7 %(56/979) when combining both techniques. The concordance rate between the tests was 97.5 %. Notably, the Xpert HPV assay was highly efficient in detecting HPV, with nearly all identified HPVs being high-risk oncogenic types, predominantly HPV16, 18, 31, 35, and 45.\u003Cbr>The Xpert HPV assay has demonstrated excellent analytical performance, making it a reliable option for HPV detection in vaginal and cervical swabs. Its integration into primary cervical cancer screening programs could significantly enhance the early detection of HPV-positive cases, thereby strengthening the screening framework and potentially reducing both the incidence and mortality of cervical cancer. Future studies should focus on confirming these results and exploring the utility of this method in conjunction with other diagnostic tools such as visual inspection with acetic acid (VIA) for a comprehensive assessment of its effectiveness in real-world settings. |\n\n1. Introduction  \nCervical cancer is the fourth most common cancer in women globally, with around 660,000 new cases and 350,000 deaths in 2022, and the highest incidence and mortality rates occur in low- and middleincome countries [1]. Human papillomaviruses (HPV) are widely recognized as the etiologic factor for cervical cancer development, and they are also implicated in neoplasms of the head and neck—particularly oropharyngeal squamous cell carcinomas—as well as other malignancies such as breast, bladder, colorectal, prostate, and penile cancers [2]. HPV is a common sexually transmitted infection that nearly  \nall sexually active individuals encounter at some point in their lives, typically without symptoms due to immune-mediated viral clearance. However, persistent infection with high-risk HPV (hrHPV) is the primary factor driving abnormal cell formation, the initiation of precancerous lesions, and progression to cervical cancer [3].  \nMore and more countries are shifting from cervical cytology-based screening to HPV-based scre","cbCaitPQBfzOLbOi","https://ap.wps.com/l/cbCaitPQBfzOLbOi","pdf",1337912,"English","# Introduction\n## Background and rationale for HPV testing\n## Molecular methods and the Xpert HPV assay","[{\"question\":\"What was the purpose of comparing GeneXpert and PCR-sequencing in this study?\",\"answer\":\"To compare assay performance for HPV detection and genotyping and to assess feasibility of incorporating HPV molecular testing into cervical cancer screening programs.\"},{\"question\":\"How many participants and valid samples were included in the analysis?\",\"answer\":\"The study recruited 1000 women; after excluding 21 invalid tests, 979 samples were analyzed.\"},{\"question\":\"What did the study report about HPV prevalence and agreement between methods?\",\"answer\":\"HPV prevalence was 4.0% by PCR and 5.0% by Xpert, with 5.7% combined, and a 97.5% concordance rate between tests.\"}]","Evaluating the performance of the Xpert HPV assay in detecting HPV positive cases in Morocco - Article | PDF",1790170670,15,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e5d17a7bb35059114935f3f558774aa.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/847fdbceb3610b248fe710e0895ec656.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37b0d2e1a323fdc9a8a94ab614bcab02.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14e6cd3a05839a95de908bf4042075f0.webp",980,1306]